Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan

Abstract

IMPORTANCE Patients with cancer and health care workers (HCWs) are at high risk of SARS-CoV-2 infection. Assessing the antibody status of patients with cancer and HCWs can help understand the spread of COVID-19 in cancer care. OBJECTIVE To evaluate serum SARS-CoV-2 antibody status in patients with cancer and HCWs during the COVID-19 pandemic in Japan. DESIGN, SETTING, AND PARTICIPANTS Participants were enrolled for this prospective cross-sectional study between August 3 and October 30, 2020, from 2 comprehensive cancer centers in the epidemic area around Tokyo, Japan. Patients with cancer aged 16 years or older and employees were enrolled. Participants with suspected COVID-19 infection at the time of enrollment were excluded. EXPOSURES Cancer of any type and cancer treatment, including chemotherapy, surgery, immune checkpoint inhibitors, radiotherapy, and targeted molecular therapy. MAIN OUTCOMES AND MEASURES Seroprevalence and antibody levels in patients with cancer and HCWs. Seropositivity was defined as positivity to nucleocapsid IgG (N-IgG) and/or spike IgG (S-IgG). Serum levels of SARS-CoV-2 IgM and IgG antibodies against the nucleocapsid and spike proteins were measured by chemiluminescent enzyme immunoassay. RESULTS A total of 500 patients with cancer (median age, 62.5 years [range, 21-88 years]; 265 men [55.4%]) and 1190 HCWs (median age, 40 years [range, 20-70 years]; 382 men [25.4%]) were enrolled.In patients with cancer, 489 (97.8%) had solid tumors, and 355 (71.0%) had received anticancer treatment within 1 month. Among HCWs, 385 (32.3%) were nurses or assistant nurses, 266 (22.4%) were administrative officers, 197 (16.6%) were researchers, 179 (15.0%) were physicians, 113 (9.5%) were technicians, and 50 (4.2%) were pharmacists. The seroprevalence was 1.0% (95% CI, 0.33%-2.32%) in patients and 0.67% (95% CI, 0.29%-1.32%) in HCWs (P = .48). However, the N-IgG and S-IgG antibody levels were significantly lower in patients than in HCWs (N-IgG: β, −0.38; 95% CI, −0.55 to −0.21; P < .001; and S-IgG: β, −0.39; 95% CI, −0.54 to −0.23; P < .001). Additionally, among patients, N-IgG levels were significantly lower in those who received chemotherapy than in those who did not (median N-IgG levels, 0.1 [interquartile range (IQR), 0-0.3] vs 0.1 [IQR, 0-0.4], P = .04). In contrast, N-IgG and S-IgG levels were significantly higher in patients who received immune checkpoint inhibitors than in those who did not (median N-

Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis

“…Overall, the subgroup analysis demonstrated that the adverse impacts of chemotherapy mainly occurred in patients with haematologic malignancies. However, for patients with solid tumors, immunotherapy could lead to life-threatening outcomes, especially when administered within 50 d. Both chemotherapy and immunotherapy were reported to affect SARS-CoV-2 antibody levels in patients and could influence the immune response to SARS-CoV-2 (Yazaki et al, 2021). In fact, some previous studies even indicated that chemotherapy increased the risk of poor outcomes (Grivas et al, 2021;Sharafeldin et al, 2021), especially in patients with haematologic malignancies (Lee et al, 2020b), which is in agreement with our results.…”

Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs

“…Moreover, this analysis confirmed the results in the chemotherapy and non-chemotherapy treated sub-groups. Likewise, two recently published articles described a reduced immune response to SARS-CoV-2 in patients with solid malignant neoplasms undergoing active cancer therapy [19,26]. Monin et al have lately reported better immunogenicity after two versus one vaccine dose in cancer patients.…”

Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy

“…Multivariable analysis showed that the only variable statistically significantly associated with lower IgG titer was treatment with chemotherapy plus immunotherapy ( 22 ). Although the evidence are lacking, it seems comorbid cancer and treatment with systemic therapy, including chemotherapy, may influence the immune response to SARS-CoV-2 and potentially COVID-19 vaccination ( 23 ).…”